Friday, April 25, 2014
08:30-10:00 |
CROHN’S DISEASE |
| Capsule |
Inflammatory bowel diseases are among the most complex and difficult to treat disorders that gastroenterologists face. Every new therapy introduced brings new questions to the table. Should we be more aggressive? How should we handle loss of response, and how should we time these interventions? This session will deal with these controversies and offer possible strategies
|
| Chairpersons | D.C. Wilson, UK P. Lionetti, Italy |
| 08:30 | Natural history: State of the Art D.C. Wilson, UK |
| 09:00 |
Debate: Early use of biologicsPro: L. De Ridder, NetherlandsCon: R. Shaoul, Israel Discussion |
10:20-11:50 |
REFRACTORY INFLAMMATORY BOWEL DISEASE (IBD) |
| Chairpersons | A. Levine, Israel |
| 10:20 |
State of the art
R. Russell, UK
State of the art
R. Russell, UK
|
| 10:50 |
New medications around the corner?
A. Levine, Israel
|
| 11:20 | Round Table Discussion |
12:10-13:40 |
MICROBIOME IN HEALTH AND DISEASE |
| Chairpersons | H. Szajewska, Poland J. Bronsky, Czech Republic |
| 12:10 | Diet and Microbiota in children living in different environments P. Lionetti, Italy |
| 12:40 | Probiotics and antibiotics in IBD and IBS H. Szajewska, Poland |
| 13:10 | Fecal transplants for infections in IBD and IBS N. Kennedy, UK |
14:30-16:00 |
PEPTIC AND ESOPHAGEAL DISEASE |
| Capsule |
Reflux symptoms and abdominal pain are among the most common complaints pediatricians and gastroenterologists have to deal with. The pendulum has swung from test (using gastroscopy and PH metry) and treat, to treat and test with proton pump inhibitors and PH impedance. Life has now been further complicated by the recognition of eosinophilic esophagitis and questions regarding optimal use of proton inhibitors. This session will shed light on these complex issues
|
| Chairperson | D. Serban, Romania |
| 14:30 | The spectrum of acid and eosiniophilic esophagitis C. Dupont, France |
| 15:00 |
Debate: Proton pump inhibitors should be:
The first line for symptomatic GER in young infants and children: D. Serban, Romania |
16:30-18:00 |
FAILURE TO THRIVE |
| Capsule |
Failure to thrive is a common disorder, and in low intake failure to thrive, improving nutritional support has become an important goal. The advances in tube feeding have improved growth but increased the number of tube dependent children. Are there alternatives?
|
| Chairpersons: | P. Lionetti, Italy S. Kolacek, Croatia |
| 16:30 |
Debate: Tubes for FTT!No: M. Dunitz, AustriaYes: S. Kolacek, Croatia Discussion |
| 17:30 | Recognition of Infantile Feeding Disorders I. Segal, Israel |
Saturday, April 26, 2014
08:30-10:00 |
LIVER DISEASE I |
| Chairperson | N. Hadzic, UK |
| 08:30 | Acute liver failure N. Hadzic, UK |
| 09:00 | Treatment of Hepatitis B and C E. Sokal, Belgium |
| 09:30 | Approach to neonatal liver disease P. McKiernan, UK |
10:20-11:50 |
LIVER DISEASE II |
| Chairperson | P. Socha, Poland |
| 10:20 |
Debate: Treatment of Hepatitis B and C should be:Initiated as early as possible: E. Sokal, BelgiumDeferred if possible Discussion |
| Round Table Discussion: Dilemmas in Hepatitis B and C |
12:10-13:40 |
CELIAC DISEASE |
| Capsule | Celiac disease (CD) is a systemic immune-mediated disorder elicited by gluten in genetically susceptible individuals. Gluten sensitivity receives much interest although the limits and possible overlap between gluten sensitivity and CD remain poorly defined. At present, a number of morphological, functional and immunological disorders that lack one or more of the key CD criteria but respond to gluten exclusion are included under the umbrella of gluten sensitivity. The possible immunological mechanisms underlying these conditions are discussed |
| Chairpersons | M.L. Mearin, Netherlands R. Troncone, Italy |
| 12:10 | State of the art: Treatment of Celiac Disease is around the corner R. Troncone, Italy |
| 12:40 |
Debate: Gluten as a cause of GI disease and intoleranceA questionable disorder: Z. Halperin, IsraelUnder diagnosed, underappreciated: M.L. Mearin, Netherlands Discussion |
14:30-16:00 |
NUTRITIONAL THERAPY |
| Chairperson | S. Kolacek, Croatia |
| 14:30 | Nutritional management of cholestasis in infants P. Socha, Poland |
| 15:00 | Diagnostic and nutritional strategies for failure to thrive C. Romano, Italy |
| 15:30 | Enteral nutrition for therapy in IBD G. Veres, Hungary |
08:30-10:00 |
HELICOBACTER PYLORI: FRIEND OR FOE? |
| Capsule |
Helicobacter pylori has been identified as the primary cause of gastritis and ulcers both in children and adults. It has been labeled public enemy number 1, and eradication has become more difficult to achieve due to bacterial resistance. But should we be searching for and eradicating H.pylori?
Join this session to find out. The answers might surprise you. |
| Chairperson | J. Bronsky, Czech Republic |
| 08:30 |
Debate: Selective eradicationH pylori is a friend: S. Hussey, IrelandH pylori is a foe!: J. Bronsky, Czech Republic |
| 09:30 | Eradication protocols: Which is the best? S. Hussey, Ireland |
Sunday, April 27, 2014
10:30-12:00 |
THE FUTURE |
| Chairpersons | A. Dahwan, UK M. Aloi, Italy |
| 10:30 | The future in pediatric liver disease A. Dahwan,UK |
| 11:00 | The future in inflammatory diseases of the gut M. Aloi, Italy |
| 11:30 |
Diet and gut microbiotica |